Discover
RIGL
Rigel Pharmaceuticals, Inc.
42.02
1 x 41.72
1 x 43.49
bid
ask
+
0.36
0.86%
2 @ 04:00 PM
42.75 +0.73 (1.74%)
| Ytd | -1.89% | |
| 1y | 25.58% |
41.11
day range
42.04
24.95
52 week range
52.24
| Open | 41.38 | Prev Close | 41.66 | Low | 41.11 | High | 42.04 | Mkt Cap | 777.46M |
| Vol | 0.00 | Avg Vol | 386.79K | EPS | 3.92 | P/E | 10.72 | Forward P/E | 19.49 |
| Beta | 0.95 | Short Ratio | 1.69 | Inst. Own | 68.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 36.88 | 200-d Avg | 35.30 | 1yr Est | 31.33 |
| Income Statement | |||
| Total Revenue | 78.70M | ||
| Revenues (USD) | 78.70M | ||
| Cost of Revenue | 8.53M | ||
| Gross Profit | 70.18M | ||
| Operating Expenses | 46.60M | ||
| Research and Development Expense | 13.96M | ||
| Selling, General and Administrative Expense | 32.64M | ||
| Operating Income | 23.58M | ||
| Interest Expense | 779.00K | ||
| Income Tax Expense | 6.30M | ||
| Net Income | 17.29M | ||
| Net Income Common Stock | 17.29M | ||
| Net Income Common Stock (USD) | 17.29M | ||
| Consolidated Income | 17.29M | ||
| Earnings per Basic Share | 0.93 | ||
| Earnings per Basic Share (USD) | 0.93 | ||
| Earnings per Diluted Share | 0.88 | ||
| Earning Before Interest & Taxes (EBIT) | 24.36M | ||
| Earning Before Interest & Taxes (USD) | 24.36M | ||
| Weighted Average Shares | 18.54M | ||
| Weighted Average Shares Diluted | 19.57M | ||
| Balance Sheet | |||
| Cash and Equivalents | 60.82M | ||
| Cash and Equivalents (USD) | 60.82M | ||
| Investments | 34.51M | ||
| Investments Current | 34.51M | ||
| Trade and Non-Trade Receivables | 56.04M | ||
| Current Assets | 185.53M | ||
| Property, Plant & Equipment Net | 647.00K | ||
| Total Assets | 521.07M | ||
| Debt Current | 39.89M | ||
| Total Debt | 39.95M | ||
| Current Liabilities | 95.59M | ||
| Debt Non-Current | 58.00K | ||
| Total Liabilities | 95.64M | ||
| Accumulated Retained Earnings (Deficit) | -997.10M | ||
| Accumulated Other Comprehensive Income | -148.00K | ||
| Shareholders Equity | 425.42M | ||
| Shareholders Equity (USD) | 425.42M | ||
| Assets Non-Current | 335.54M | ||
| Total Debt (USD) | 39.95M | ||
| Deferred Revenue | 27.97M | ||
| Goodwill and Intangible Assets | 93.88M | ||
| Inventory | 14.37M | ||
| Liabilities Non-Current | 58.00K | ||
| Trade and Non-Trade Payables | 4.01M | ||
| Tax Assets | 238.07M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 848.00K | ||
| Net Cash Flow from Financing | -11.70M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 36.41M | ||
| Capital Expenditure | -70.35M | ||
| Issuance (Purchase) of Equity Shares | 1.35M | ||
| Issuance (Repayment) of Debt Securities | -8.05M | ||
| Net Cash Flow from Investing | 17.45M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 87.80M | ||
| Net Cash Flow from Operations | 30.65M | ||
| Share Based Compensation | 6.84M | ||